| US 7,550,425 B2 | ||
| Diuretic peptide conjugates | ||
| Bjarne Due Larsen, Roskilde (Denmark); Jørgen Søberg Petersen, Hellebaek (Denmark); Daniel R. Kapusta, Slidell, La. (US); and Kenneth W. Harlow, Frederiksberg (Denmark) | ||
| Assigned to Zealand Pharma A/S, Glostrup (Denmark) | ||
| Filed on Apr. 08, 2005, as Appl. No. 11/102,564. | ||
| Application 11/102564 is a continuation of application No. 09/882291, filed on Jun. 15, 2001, granted, now 7,244,701. | ||
| Claims priority of provisional application 60/298186, filed on Jun. 13, 2001. | ||
| Claims priority of provisional application 60/251671, filed on Dec. 06, 2000. | ||
| Claims priority of application No. 2000 00944 (DK), filed on Jun. 16, 2000; and application No. 2000 01486 (DK), filed on Oct. 05, 2000. | ||
| Prior Publication US 2006/0052284 A1, Mar. 09, 2006 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. A61K 38/00 (2006.01); A61K 38/04 (2006.01); A61K 38/08 (2006.01); A61K 38/10 (2006.01); C07K 7/00 (2006.01) | ||
| U.S. Cl. 514—2 [530/300; 530/326; 530/327; 530/328] | 31 Claims |
| 1. A peptide conjugate of formula III
R1-X-Z′-R2 (SEQ ID NO: 81) (III)
wherein X represents
(RK)YY(RK)(WI)(RK) (II)
wherein alternative amino acid residues at positions 1, 4, 5, and 6 are shown in brackets;
Z′ is selected from the group consisting of K8 (SEQ ID NO:73), K7 (SEQ ID NO:74), K6 (SEQ ID NO:75), K5 (SEQ ID NO:76), and K4 (SEQ ID NO:77) wherein the amino acid residues have the D or L configuration;
R1 represents H or an acyl group;
R2 represents NR3R4 where each of R3 and R4 independently represents hydrogen, C(1-6)alkoxy, aryloxy, or a lower alkyl; or R2 represents OH; or
a salt, hydrate, or solvate thereof, or an all-D form, a retro form, or a retro all-D form thereof.
|